Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 34

1.

How does binding of agonist ligands control intrinsic molecular dynamics in human NMDA receptors?

Palmai Z, Houenoussi K, Cohen-Kaminsky S, Tchertanov L.

PLoS One. 2018 Aug 3;13(8):e0201234. doi: 10.1371/journal.pone.0201234. eCollection 2018.

2.

Germline CDKN2A/P16INK4A mutations contribute to genetic determinism of sarcoma.

Jouenne F, Chauvot de Beauchene I, Bollaert E, Avril MF, Caron O, Ingster O, Lecesne A, Benusiglio P, Terrier P, Caumette V, Pissaloux D, de la Fouchardière A, Cabaret O, N'Diaye B, Velghe A, Bougeard G, Mann GJ, Koscielny S, Barrett JH, Harland M, Newton-Bishop J, Gruis N, Van Doorn R, Gauthier-Villars M, Pierron G, Stoppa-Lyonnet D, Coupier I, Guimbaud R, Delnatte C, Scoazec JY, Eggermont AM, Feunteun J, Tchertanov L, Demoulin JB, Frebourg T, Bressac-de Paillerets B.

J Med Genet. 2017 Sep;54(9):607-612. doi: 10.1136/jmedgenet-2016-104402. Epub 2017 Jun 7.

3.

Insight on Mutation-Induced Resistance from Molecular Dynamics Simulations of the Native and Mutated CSF-1R and KIT.

Da Silva Figueiredo Celestino Gomes P, Chauvot De Beauchêne I, Panel N, Lopez S, De Sepulveda P, Geraldo Pascutti P, Solary E, Tchertanov L.

PLoS One. 2016 Jul 28;11(7):e0160165. doi: 10.1371/journal.pone.0160165. eCollection 2016.

4.

How Intrinsic Molecular Dynamics Control Intramolecular Communication in Signal Transducers and Activators of Transcription Factor STAT5.

Langenfeld F, Guarracino Y, Arock M, Trouvé A, Tchertanov L.

PLoS One. 2015 Dec 30;10(12):e0145142. doi: 10.1371/journal.pone.0145142. eCollection 2015.

5.

Evidence of a target resistance to antivitamin K rodenticides in the roof rat Rattus rattus: identification and characterisation of a novel Y25F mutation in the Vkorc1 gene.

Goulois J, Chapuzet A, Lambert V, Chatron N, Tchertanov L, Legros L, Benoît E, Lattard V.

Pest Manag Sci. 2016 Mar;72(3):544-50. doi: 10.1002/ps.4020. Epub 2015 May 26.

PMID:
25847836
6.

Genetic evidence of a precisely tuned dysregulation in the hypoxia signaling pathway during oncogenesis.

Couvé S, Ladroue C, Laine E, Mahtouk K, Guégan J, Gad S, Le Jeune H, Le Gentil M, Nuel G, Kim WY, Lecomte B, Pagès JC, Collin C, Lasne F, Benusiglio PR, Bressac-de Paillerets B, Feunteun J, Lazar V, Gimenez-Roqueplo AP, Mazure NM, Dessen P, Tchertanov L, Mole DR, Kaelin W, Ratcliffe P, Richard S, Gardie B.

Cancer Res. 2014 Nov 15;74(22):6554-64. doi: 10.1158/0008-5472.CAN-14-1161. Epub 2014 Nov 4.

7.

Allosteric pathway identification through network analysis: from molecular dynamics simulations to interactive 2D and 3D graphs.

Allain A, Chauvot de Beauchêne I, Langenfeld F, Guarracino Y, Laine E, Tchertanov L.

Faraday Discuss. 2014;169:303-21. doi: 10.1039/c4fd00024b. Epub 2014 May 30.

PMID:
25340971
8.

Characterization of S628N: a novel KIT mutation found in a metastatic melanoma.

Vita M, Tisserand JC, Chauvot de Beauchêne I, Panel N, Tchertanov L, Agopian J, Mescam-Mancini L, Fouet B, Fournier B, Dubreuil P, Bertucci F, De Sepulveda P.

JAMA Dermatol. 2014 Dec;150(12):1345-9.

PMID:
25317746
9.

HSP70 sequestration by free α-globin promotes ineffective erythropoiesis in β-thalassaemia.

Arlet JB, Ribeil JA, Guillem F, Negre O, Hazoume A, Marcion G, Beuzard Y, Dussiot M, Moura IC, Demarest S, de Beauchêne IC, Belaid-Choucair Z, Sevin M, Maciel TT, Auclair C, Leboulch P, Chretien S, Tchertanov L, Baudin-Creuza V, Seigneuric R, Fontenay M, Garrido C, Hermine O, Courtois G.

Nature. 2014 Oct 9;514(7521):242-6. doi: 10.1038/nature13614. Epub 2014 Aug 24.

PMID:
25156257
10.

Hotspot mutations in KIT receptor differentially modulate its allosterically coupled conformational dynamics: impact on activation and drug sensitivity.

Chauvot de Beauchêne I, Allain A, Panel N, Laine E, Trouvé A, Dubreuil P, Tchertanov L.

PLoS Comput Biol. 2014 Jul 31;10(7):e1003749. doi: 10.1371/journal.pcbi.1003749. eCollection 2014 Jul.

11.

Differential effects of CSF-1R D802V and KIT D816V homologous mutations on receptor tertiary structure and allosteric communication.

Da Silva Figueiredo Celestino Gomes P, Panel N, Laine E, Pascutti PG, Solary E, Tchertanov L.

PLoS One. 2014 May 14;9(5):e97519. doi: 10.1371/journal.pone.0097519. eCollection 2014.

12.

Co-operating STAT5 and AKT signaling pathways in chronic myeloid leukemia and mastocytosis: possible new targets of therapy.

Bibi S, Arslanhan MD, Langenfeld F, Jeanningros S, Cerny-Reiterer S, Hadzijusufovic E, Tchertanov L, Moriggl R, Valent P, Arock M.

Haematologica. 2014 Mar;99(3):417-29. doi: 10.3324/haematol.2013.098442. Review.

13.

Further characterisation of rotavirus cores: Ss(+)RNAs can be packaged in vitro but packaging lacks sequence specificity.

Desselberger U, Richards J, Tchertanov L, Lepault J, Lever A, Burrone O, Cohen J.

Virus Res. 2013 Dec 26;178(2):252-63. doi: 10.1016/j.virusres.2013.09.034. Epub 2013 Oct 1.

14.

Raltegravir flexibility and its impact on recognition by the HIV-1 IN targets.

Arora R, de Beauchene IC, Polanski J, Laine E, Tchertanov L.

J Mol Recognit. 2013 Sep;26(9):383-401. doi: 10.1002/jmr.2277.

PMID:
23836466
15.

Allosteric communication across the native and mutated KIT receptor tyrosine kinase.

Laine E, Auclair C, Tchertanov L.

PLoS Comput Biol. 2012;8(8):e1002661. doi: 10.1371/journal.pcbi.1002661. Epub 2012 Aug 23.

16.

In Silico and In Vitro Comparison of HIV-1 Subtypes B and CRF02_AG Integrases Susceptibility to Integrase Strand Transfer Inhibitors.

Ni X, Abdel-Azeim S, Laine E, Arora R, Osemwota O, Marcelin AG, Calvez V, Mouscadet JF, Tchertanov L.

Adv Virol. 2012;2012:548657. doi: 10.1155/2012/548657. Epub 2012 Jul 5.

17.

Ethyl malonate amides: a diketo acid offspring fragment for HIV integrase inhibition.

Serafin K, Mazur P, Bak A, Laine E, Tchertanov L, Mouscadet JF, Polanski J.

Bioorg Med Chem. 2011 Aug 15;19(16):5000-5. doi: 10.1016/j.bmc.2011.06.054. Epub 2011 Jun 29.

PMID:
21767953
18.

Mutation D816V alters the internal structure and dynamics of c-KIT receptor cytoplasmic region: implications for dimerization and activation mechanisms.

Laine E, Chauvot de Beauchêne I, Perahia D, Auclair C, Tchertanov L.

PLoS Comput Biol. 2011 Jun;7(6):e1002068. doi: 10.1371/journal.pcbi.1002068. Epub 2011 Jun 16.

19.

Resistance to HIV-1 integrase inhibitors: A structural perspective.

Mouscadet JF, Delelis O, Marcelin AG, Tchertanov L.

Drug Resist Updat. 2010 Aug-Oct;13(4-5):139-50. doi: 10.1016/j.drup.2010.05.001. Epub 2010 Jun 8. Review.

PMID:
20570551
20.

Raltegravir: molecular basis of its mechanism of action.

Mouscadet JF, Tchertanov L.

Eur J Med Res. 2009 Nov 24;14 Suppl 3:5-16. Review.

21.

Impact of Y143 HIV-1 integrase mutations on resistance to raltegravir in vitro and in vivo.

Delelis O, Thierry S, Subra F, Simon F, Malet I, Alloui C, Sayon S, Calvez V, Deprez E, Marcelin AG, Tchertanov L, Mouscadet JF.

Antimicrob Agents Chemother. 2010 Jan;54(1):491-501. doi: 10.1128/AAC.01075-09. Epub 2009 Nov 9.

22.

HIV-1 IN alternative molecular recognition of DNA induced by raltegravir resistance mutations.

Mouscadet JF, Arora R, André J, Lambry JC, Delelis O, Malet I, Marcelin AG, Calvez V, Tchertanov L.

J Mol Recognit. 2009 Nov-Dec;22(6):480-94. doi: 10.1002/jmr.970.

PMID:
19623602
23.

Genetic barriers for integrase inhibitor drug resistance in HIV type-1 B and CRF02_AG subtypes.

Maïga AI, Malet I, Soulie C, Derache A, Koita V, Amellal B, Tchertanov L, Delelis O, Morand-Joubert L, Mouscadet JF, Murphy R, Cissé M, Katlama C, Calvez V, Marcelin AG.

Antivir Ther. 2009;14(1):123-9.

PMID:
19320246
24.

Quasispecies variant dynamics during emergence of resistance to raltegravir in HIV-1-infected patients.

Malet I, Delelis O, Soulie C, Wirden M, Tchertanov L, Mottaz P, Peytavin G, Katlama C, Mouscadet JF, Calvez V, Marcelin AG.

J Antimicrob Chemother. 2009 Apr;63(4):795-804. doi: 10.1093/jac/dkp014. Epub 2009 Feb 16.

PMID:
19221102
25.

The G140S mutation in HIV integrases from raltegravir-resistant patients rescues catalytic defect due to the resistance Q148H mutation.

Delelis O, Malet I, Na L, Tchertanov L, Calvez V, Marcelin AG, Subra F, Deprez E, Mouscadet JF.

Nucleic Acids Res. 2009 Mar;37(4):1193-201. doi: 10.1093/nar/gkn1050. Epub 2009 Jan 7.

26.

Structural effects of amino acid variations between B and CRF02-AG HIV-1 integrases.

Malet I, Soulie C, Tchertanov L, Derache A, Amellal B, Traore O, Simon A, Katlama C, Mouscadet JF, Calvez V, Marcelin AG.

J Med Virol. 2008 May;80(5):754-61. doi: 10.1002/jmv.21169.

PMID:
18360887
27.

Mutations associated with failure of raltegravir treatment affect integrase sensitivity to the inhibitor in vitro.

Malet I, Delelis O, Valantin MA, Montes B, Soulie C, Wirden M, Tchertanov L, Peytavin G, Reynes J, Mouscadet JF, Katlama C, Calvez V, Marcelin AG.

Antimicrob Agents Chemother. 2008 Apr;52(4):1351-8. doi: 10.1128/AAC.01228-07. Epub 2008 Jan 28.

28.
29.
30.

A New Manganese Dinuclear Complex with Phenolate Ligands and a Single Unsupported Oxo Bridge. Storage of Two Positive Charges within Less than 500 mV. Relevance to Photosynthesis.

Horner O, Anxolabéhère-Mallart E, Charlot MF, Tchertanov L, Guilhem J, Mattioli TA, Boussac A, Girerd JJ.

Inorg Chem. 1999 Mar 22;38(6):1222-1232.

PMID:
11670906
31.

Preparation of novel polysubstituted chiral cyclohexanone derivatives containing a quaternary carbon by Ferrier reaction.

Hladezuk I, Olesker A, Tchertanov L, Cléophax J.

Carbohydr Res. 2001 Jan 30;330(2):257-65.

PMID:
11217979
32.
33.

Structural metrics relationships in covalently bonded organic azides.

Tchertanov L.

Acta Crystallogr B. 1999 Oct 1;55(Pt 5):807-809.

PMID:
10927421
34.

D-ring substituted rhazinilam analogues: semisynthesis and evaluation of antitubulin activity.

Dupont C, Guénard D, Tchertanov L, Thoret S, Guéritte F.

Bioorg Med Chem. 1999 Dec;7(12):2961-9.

PMID:
10658602

Supplemental Content

Loading ...
Support Center